References
- Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in 'good-risk' chronic granulocytic leukemia. Blood 1984; 63: 789–799.
- Hasford J, Pfirrmann M, Hehlmann R et al. A new pro-gnostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850–858.
- Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.
- Menzin J, Lang K, Earle CC, Glendenning A. Treatment patterns,outcomes and costs among elderly patients with chronic myeloid leukaemia: a population-based analysis. Drugs Aging 2004; 21: 737–746.
- Cortes J, Talpaz M, O'Brien S et al. Effects of age on prognosiswith imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003; 98: 1105–1113.
- Latagliata R, Breccia M, Carmosino I et al. Elderly patients withPh+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Erratum appears in Leuk Res 2005; 29(9): 1099.
- Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, HensleyML et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.
- Colombat M, Fort MP, Chollet C et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haemarologica 2006; 91: 162–168.
- Rosti G, Iacobucci I, Bassi S, Castagnetti F et al. Impact of age onthe outcome of patients with chronic myeloid leukaemia in late chronic phase: results of a phase II study of the GIMEMA CML working party. Haematologica 2007; 92; 101–105.
- Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988; 25: 49–61.
- Gabert J, Beillard E, van der Velden VH et al. Standardization andquality control studies of 'real-time' quantitative reverse transcrip-tase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia — a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.
- McCallum L, Price S, Planque N et al. A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 2006; 108: 1716–1723.
- Cortes J, Kantarjian H, O'Brien S, Robertson LE, Pierce S, Talpaz M. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996; 100: 452–455.
- Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006; 20: 29–41.